FDA Expands Afrezza to Pediatric Diabetes - Takeaways - MDSpire

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

Share

1

The FDA has approved Afrezza for children aged 6 and older with type 1 or type 2 diabetes.
2

Afrezza is an inhaled mealtime insulin that is administered using a portable inhaler.
3

The approval was supported by data from the INHALE-1 trial and over 20 years of inhaled insulin studies.
4

Afrezza offers a needle-free option for mealtime insulin, addressing challenges faced by pediatric patients.
5

Afrezza is not suitable for patients with chronic lung diseases and requires lung function assessments.